Anti-IL-21R [ATR-107]

Absolute Antibody

Anti-IL-21R [ATR-107]

9

This antibody recognises both human and murine IL-21R extracellular domains, as both were used as targets during alternating rounds of phage display library panning. This antibody also binds to rat and cynomolgus monkey IL-21R, but does not cross-react wi

This antibody binds to both human and murine IL-21R; surface plasmon resonance analysis has revealed this antibody to have an affinity to human and cynomolgus monkey IL-21R of 2 nM, and to murine IL-21R of 16 nM (Vugmeyster et al, 2010). This antibody has been shown to neutralise the IL-21-dependent proliferation of both activated human primary B and CD4+ T cells and mouse CD8+ T cells (Vugmeyster et al, 2010). Additionally, this antibody inhibits IL-21-induced phosphorylation of STAT3 in CD4+ T cells in a concentration-dependent manner (Zhu et al, 2013). In the MRL-Faslpr mouse model of lupus, administration of this antibody has been shown to reduce anti-dsDNA antibodies and IgG deposits in the kidney (Vugmeyster et al, 2010). This antibody did not induce cytokine storm-associated gene activation in human PBMCs in vitro, nor when administered to cynomolgus monkeys (Guo et al, 2010). When administered to humans as part of a phase I trial, this antibody was highly immunogenic, with a prolonged pharmacodynamic effect, but was observed to lead to the development of anti-drug antibodies in 75% of subjects (Hua et al, 2013).

Neutralisation/Blocking

Research Use Only

Monoclonal

ATR-107

IL21R

interleukin 21 receptor

CD360; IL-21 receptor; IMD56; interleukin-21 receptor; NILR; novel interleukin receptor

Human

IgG1

Interleukin-21 receptor

Human, Monkey, Mouse

-20°C,2°C to 8°C

12352203